UNH UnitedHealth Group 10-Q 2026-09-30 section summaries

UnitedHealth Group — Q3 and nine months ended September 30, 2026

Consolidated results

Q3 revenue declined 0.4%, while operating earnings and attributable net earnings increased as medical and operating costs fell. Nine-month revenue grew 0.6%; operating earnings and net earnings also rose. Nine-month cost of products sold was $39.905B versus $37.975B, and depreciation and amortization was $3.142B versus $3.244B.

Segment performance

Optum Health remained the main segment revenue weakness: Q3 revenue declined 9.9%, compared with a 6.0% decline for the first nine months ($70.491B versus $74.984B). Its nine-month operating earnings were $3.066B versus $1.881B. Optum Financial, including Optum Bank, was realigned from Optum Health to Optum Insight effective January 1, 2026; prior-period segment figures were recast. Segment operating earnings total consolidated operating earnings. Below operating earnings, consolidated interest expense was $963M versus $1.003B in Q3; loss on sale of subsidiaries held for sale was $76M versus $83M.

Cash flow and capital allocation

Operating cash flow benefited from a $2.560B cash source from accounts receivable, versus $65M in 9M 2025. The medical-costs-payable cash-flow change was a $49M use, compared with a $6.178B source in the prior-year period. Cash at September 30, 2026 was $25.845B, versus $27.210B a year earlier. Shares outstanding declined from 906M at the start of 2026 to 896M at September 30.

The June 2026 board increase raised the annualized dividend rate to $9.28 per share from $8.84; Q3 dividend payments were $2.078B. Forward repurchase contracts covering up to $2.0B were settled July 1: the counterparty purchased 6.4M shares at an average $312.73 per share. In November, the board authorized repurchases of up to 50M additional shares, beyond remaining authorization under the 2024 renewal.

Balance sheet and reserves

Equity less goodwill and other intangible assets was negative $29.222B at September 30, 2026. Commercial paper outstanding was $2.9B, at a 3.9% weighted-average annual interest rate. Long-term debt and other financing obligations had fair value of $63.481B versus carrying value of $71.391B at September 30; at year-end 2025, fair value was $72.143B versus carrying value of $76.140B.

Medical costs payable was $39.352B at September 30, 2026, versus $40.181B a year earlier, and began the year at $39.337B. Reserves for incurred-but-not-reported claims were $26.7B at both September 30 and December 31, 2025. Nine-month medical payments were $225.970B versus $226.001B. Favorable prior-year reserve development was $1.440B in 9M 2026, mainly reflecting a favorable respiratory illness season, compared with a $30M reserve reduction in 9M 2025.

Portfolio actions, investments, and risks

A strategic review begun in Q4 2025 focused on advancing and scaling core operations, including Optum Health’s value-based-care business. Portfolio actions generated gains of $224M in Q3 and $415M in 9M 2026. Restructuring and other actions included loss-contract reserve decreases of $95M in Q3 and $282M year to date; the nine-month period also included a $400M United Health Foundation contribution funded from Optum Insight disposition proceeds. These actions increased nine-month operating costs by $415M, partly offset by a $282M reduction in medical costs and a $54M increase in investment and other income.

Other dispositions generated $1.1B of cash proceeds and a $211M net gain in 9M 2026: Optum Insight recorded a $525M gain and Optum Health a $314M loss. The planned sale of remaining South American operations was expected to close in Q4, subject to approvals and other conditions. At September 30, that disposal group had $961M of assets and $987M of liabilities after a $1.732B remeasurement to fair value less cost to sell, including $964M of cumulative foreign-currency translation losses and $281M attributable to noncontrolling interests. Another held-for-sale group had $449M of assets and $339M of liabilities after a $450M remeasurement.

Debt securities had $54.314B amortized cost and $50.754B fair value at September 30, including available-for-sale securities with $53.841B amortized cost and $50.288B fair value. Available-for-sale gross unrealized losses were $3.592B, up from $1.625B at year-end 2025; $2.267B had persisted for at least 12 months. Management attributed losses primarily to higher interest rates, said it did not intend to sell securities in unrealized-loss positions, and considered losses temporary; credit-loss allowances were immaterial. Nine-month other comprehensive loss was $1.873B, largely reflecting investment-security losses. Recurring fair-value assets totaled $79.136B: $21.720B Level 1, $56.081B Level 2, and $1.335B Level 3. Equity securities were $6.0B and equity-method investments $4.0B. Held-to-maturity debt securities had $466M fair value and $473M carrying value; loan receivables had $10.425B fair value and $10.730B carrying value.

A $2.2B, 364-day uncommitted receivables-financing facility supported receivables sales of $2.8B in Q3 and $5.9B in 9M. Of $5.5B collected from counterparties, $1.5B had not yet been remitted to financial institutions; related losses were immaterial. A July acquisition cost $3.0B, half paid in cash and half payable within one year; the $1.5B payable remained outstanding at quarter-end.

The company faces litigation and government investigations, including CMS and OIG risk-adjustment data-validation audits that could result in retrospective health-plan payment adjustments. In a long-running DOJ False Claims Act case concerning risk-adjustment submissions, a court-appointed Special Master recommended summary judgment for the company in March 2025; the DOJ moved to reject that recommendation the following month, and the outcome could not be reasonably estimated. The IRS issued proposed adjustments in March 2026 concerning 2017–2020 intercompany transfer pricing that could significantly increase taxable income and potentially extend to later years. The company disputes the adjustments and said its uncertain-tax-position reserves were adequate based on information available at September 30, 2026.

UNH — Part I, Item 2: Q3 and nine months ended September 30, 2026

Consolidated results

Q3 revenue was nearly flat, as lower premium revenue was offset by growth in products and services. Medical costs declined, contributing to improved MCR and operating earnings. The lower medical costs reflected fewer people served and favorable prior-period reserve development, partly offset by elevated medical trends. Those trends include higher provider reimbursement under the No Surprises Act and increased commercial service use and coding intensity.

Segment results

*Nine-month figures shown where year-to-date growth differed materially from the quarter’s trend. Optum eliminations were $(1.428)B in Q3 2026 versus $(1.244)B in Q3 2025, and $(4.152)B for 9M 2026 versus $(3.546)B for 9M 2025. Consolidated revenue eliminations were $(40.519)B versus $(43.086)B in Q3 and $(118.460)B versus $(123.725)B for 9M.

Optum Health earnings benefited from favorable reserve development, a net decrease in loss-contract reserves and Q3 portfolio divestitures, while elevated medical cost trends remained a headwind. Optum Insight results reflected growth in business and technology services and higher investment and other income; its nine-month earnings also benefited from divestitures, partly offset by restructuring and growth-support investments. Optum Rx growth in retail and specialty pharmacy was partly offset by fewer prescriptions as UnitedHealthcare served fewer people.

Operating metrics

UnitedHealthcare medical membership declined by 1.825M year over year; Community and Senior membership fell by 1.650M. Contraction reflected benefit and pricing actions, reduced Medicaid eligibility and a state exit. Medicare Advantage faces funding pressure: multiyear rate shortfalls remain below forward medical cost trends despite the 2027 Final Notice moving toward those trends, and risk-adjustment changes further reduce funding, particularly for members with significant health and social needs. The company is responding through cost management, network and benefit changes, member premiums and county-by-county participation decisions. Medicaid care activity—especially behavioral, pharmacy and home health—is outpacing state rate updates. Commercial medical costs remain elevated, with provider pricing, bundled services, dispute-resolution impacts and aggressive billing cited. The company said it would rebate 2026 profits on individual-exchange products to customers.

Cash flow and capital allocation

Operating cash flow improved by $6.498B, which management attributed to higher earnings, timing of government payments, favorable working capital and Inflation Reduction Act changes affecting pharmacy rebates. Total cash sources were $27.545B versus $25.244B; total uses were $26.309B versus $23.342B. Including cash within businesses held for sale, cash increased $1.225B versus $1.927B.

At September 30, cash, cash equivalents, available-for-sale debt securities and marketable equity securities totaled $78.3B: $25.8B cash and cash equivalents (including $1.2B available for general corporate use), $50.3B debt securities and $2.2B marketable equity securities. Loan receivables were $11.5B. The available-for-sale debt portfolio had a 4.3-year weighted-average duration and a “Double A” weighted-average credit rating. UNH repurchased approximately 13.8M shares during 9M at an average $359.55 per share, including 6.4M shares at an average $312.73 under forward contracts settled July 1; 7.2M shares remained authorized. The annualized quarterly dividend rate rose to $9.28 per share from $8.84 in June.

Portfolio actions, outlook and risks

Q3 net portfolio divestiture actions produced a $224M gain; 9M gains totaled $415M. The actions followed a 2025 strategic review focused on core operations, including Optum Health value-based care, and included sales, businesses held for sale, an asset sale and remaining South American operations. Restructuring included reductions in loss-contract reserves of $95M in Q3 and $282M for 9M. A $400M United Health Foundation contribution in 9M was funded by an Optum Insight business-disposition gain. Optum Financial, including Optum Bank, moved from Optum Health to Optum Insight on January 1, 2026; prior segment figures were recast.

Management reported compliance with bank-facility covenants and considered resources sufficient for liquidity needs, but access to financing and its cost remain sensitive to operating cash flow, debt, ratings, covenants, regulation and markets. Senior unsecured ratings were Moody’s A2 Negative, S&P A+ Negative, Fitch A Negative and A.M. Best A− Stable. Regulated insurance and HMO subsidiaries must maintain statutory capital. Principal risks include medical-cost pricing and management; government-program revenue and cash flows; Medicare/CMS ratings, risk-adjustment audits and DOJ actions; cyber and privacy incidents; litigation and regulatory investigations; execution of value-based care, technology and AI initiatives; transaction integration and South America divestiture risks; investment performance, impairment of goodwill or intangibles, and access to subsidiary or external funding. Medical costs payable and goodwill remain critical accounting estimates.

Interest-rate risk

As of September 30, 2026, UnitedHealth Group manages interest-rate exposure by diversifying fixed-income investments and debt maturities, and by matching certain floating-rate assets and liabilities directly or through interest-rate swaps. Unrealized gains and losses on available-for-sale debt securities are reported in comprehensive income.

The modeled effects of parallel rate changes are:

The modeled annual net interest-income effect is positive when rates rise and negative when rates fall. The sensitivity analysis assumes rates do not fall below zero, so its estimated effects may not reflect the full 100- or 200-basis-point decrease.

Management, under the supervision of the CEO and CFO, evaluated UNH’s disclosure controls and procedures as of September 30, 2026, and concluded they were effective at the reasonable-assurance level. During Q3 2026, no changes in internal control over financial reporting materially affected, or were reasonably likely to materially affect, those controls. This section reports no financial metrics or other material business developments.

UNH reported no material changes to the risk factors described in its 2025 Form 10-K. It cautioned that risks not currently known, or currently considered immaterial, could still materially adversely affect its business, financial condition, or future results. No new financial metrics or strategic developments were provided in this section.

For the quarter ended September 30, 2026, no UNH directors or officers adopted or terminated a Rule 10b5-1 trading plan or a non-Rule 10b5-1 trading arrangement. This section reported no financial metrics or other material business developments.